Core Insights - Serina Therapeutics, Inc. has successfully closed a $5 million financing round from strategic shareholders to support the development of its lead clinical candidate SER-252 for Advanced Parkinson's disease [1][2] - The financing reflects investor confidence in SER-252's potential to provide continuous dopaminergic stimulation, which may offer significant clinical benefits for patients [2] - SER-252 is designed to reduce levodopa-related motor complications and improve patient comfort through a long-acting subcutaneous injection [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [5] - The company utilizes its proprietary POZ Platform, which enhances drug delivery and efficacy across various therapeutic modalities [5] Product Details - SER-252 (POZ-apomorphine) is an investigational therapy that aims to provide continuous dopaminergic stimulation, potentially reducing dyskinesia in advanced Parkinson's patients [3] - The drug leverages Enable Injections' enFuse wearable drug delivery platform for improved patient experience [3] Technology Platform - The POZ Platform is based on a synthetic polymer that allows for better control over drug loading and release rates, addressing limitations of existing drugs [4] - This technology has the potential to enhance the therapeutic profiles of various drug candidates, including small molecules and RNA-based therapeutics [4]
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease